 NEW YORK and LONDON, Sept. 07, 2021 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement C5 andor leukotriene LTB4 systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. 